search
Back to results

Study of Monitoring Exhaled NO in Symptomatic Asthmatic Adults and Children During Anti-inflammatory Treatment (eNOugh)

Primary Purpose

Asthma

Status
Completed
Phase
Not Applicable
Locations
International
Study Type
Interventional
Intervention
The Aerocrine NIOX MINO® Airway Inflammation Monitor
Sponsored by
Aerocrine AB
About
Eligibility
Locations
Outcomes
Full info

About this trial

This is an interventional diagnostic trial for Asthma focused on measuring Asthma, adult, paediatric, NIOX MINO®, NIOX®, nitric oxide, airway inflammation, open-label, single-cohort

Eligibility Criteria

4 Years - 65 Years (Child, Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Children, and adults.
  • A history of physician-diagnosed asthma or asthma diagnosed by a physician.
  • Spirometry performed parameters.
  • An increased FENO value.
  • Symptomatic asthma as defined on the Asthma Control Questionnaire® (ACQ).

Exclusion Criteria:

  • Use of oral corticosteroids.
  • Use of intranasal corticosteroids.
  • Use of non-steroidal anti-asthma drugs.
  • Current serious conditions and/or therapies that are confounding factors.
  • Pregnancy.
  • Other significant respiratory diseases and/or cardiovascular diseases.
  • Current participation in another interventional clinical study.
  • Inability to comply with the study procedures, e.g. spirometry and FENO measurements according to standard procedures.
  • Unwillingness to sign informed consent and comply with treatment and visits.
  • Smoking within 6 months before the study, or a smoking history of >10 pack years or an equivalent amount of other tobacco use.
  • Known alcohol or drug abuser.
  • Food and beverage (other than water) intake within 1 hour before first FENO measurement
  • Nicotine (including nicotine chewing gum, nicotine patch, snuff etc) use within 1 hour before first FENO measurement.
  • Strenuous exercise within 1 hour before first FENO measurement

Sites / Locations

  • Näsets Läkargrupp, Falsterbov. 79, SE-23651 Höllviken
  • Department of General Practice & Primary Care University of Aberdeen

Outcomes

Primary Outcome Measures

The primary analysis variable will be the percent change in FENO measured with
NIOX MINO® and NIOX® between Visit 1 to Visit 2.

Secondary Outcome Measures

Agreement between NIOX MINO® and NIOX® will be assessed by comparing
individual pair-wise FENO measurements from visit V1.
The change in FENO measured with NIOX MINO following corticosteroid therapy
in asthma will be compared with improvements in standard asthma outcome
measures (asthma symptoms and spirometry).
To investigate the inter-operator variability FENO measurements with
NIOX MINO in the same subject when different operators take FENO measurements. Three operator each takes two completed measurements in the same subject in a point of care setting.

Full Information

First Posted
October 16, 2006
Last Updated
November 3, 2011
Sponsor
Aerocrine AB
search

1. Study Identification

Unique Protocol Identification Number
NCT00388570
Brief Title
Study of Monitoring Exhaled NO in Symptomatic Asthmatic Adults and Children During Anti-inflammatory Treatment
Acronym
eNOugh
Official Title
A Multicenter, Device Randomized, Open-label Prospective Single-cohort Study of Monitoring Exhaled NO in Symptomatic Asthmatic Adults and Children During Anti-inflammatory Treatment
Study Type
Interventional

2. Study Status

Record Verification Date
November 2011
Overall Recruitment Status
Completed
Study Start Date
October 2006 (undefined)
Primary Completion Date
June 2007 (Actual)
Study Completion Date
July 2007 (Actual)

3. Sponsor/Collaborators

Name of the Sponsor
Aerocrine AB

4. Oversight

Data Monitoring Committee
No

5. Study Description

Brief Summary
The purpose of this study is to demonstrate substantial equivalence between two medical devices which measure nitric oxide in exhaled breath, NIOX MINO® and NIOX® in Symptomatic Asthmatic Adults and Children.
Detailed Description
Asthma is a chronic inflammatory disorder of the airways. Chronically inflamed airways are hyperresponsive; they become obstructed and airflow is limited (by bronchoconstriction, mucus plugs, and increased inflammation) when airways are exposed to various risk factors. Asthma causes recurring episodes of wheezing, breathlessness, chest tightness, and coughing particularly at night or in the early morning. NO is an important endogenous regulatory molecule that is widely distributed throughout the body. The detection of NO in exhaled air was first reported in 1991, and, soon after it was shown that the levels NO in exhaled air are elevated in patients with asthma. There is now much evidence showing that measurement of the concentration of NO in exhaled air offers a useful non-invasive method of assessing inflammatory airway disease. Exhaled NO is not increased during bronchospasm unless there is coexisting inflammation. Exhaled NO may have a valuable role in differentiating between the inflammatory and bronchospastic components of clinical asthma, and is also useful for guiding the therapeutic use of steroids and other anti-inflammatory agents. A study on asthmatics and non-asthmatics subjects has shown that substantial equivalence exists between the stationary device NIOX® and the hand held device NIOX MINO® when comparing NO measurements, when similar conditions are considered and examinations are made as consistently as possible. In a study with the stationary device NIOX®, exhaled NO was measured before and after two weeks of inhaled corticosteroid treatment in unstable steroid-naïve adult and paediatric asthmatic subjects. The result was a 50.5% mean reduction of exhaled NO. The change in exhaled NO was also compared to change in standard asthma outcome measures, asthma symptoms and spirometry.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Asthma
Keywords
Asthma, adult, paediatric, NIOX MINO®, NIOX®, nitric oxide, airway inflammation, open-label, single-cohort

7. Study Design

Primary Purpose
Diagnostic
Study Phase
Not Applicable
Interventional Study Model
Single Group Assignment
Masking
ParticipantInvestigator
Allocation
Randomized
Enrollment
151 (Actual)

8. Arms, Groups, and Interventions

Intervention Type
Device
Intervention Name(s)
The Aerocrine NIOX MINO® Airway Inflammation Monitor
Primary Outcome Measure Information:
Title
The primary analysis variable will be the percent change in FENO measured with
Title
NIOX MINO® and NIOX® between Visit 1 to Visit 2.
Secondary Outcome Measure Information:
Title
Agreement between NIOX MINO® and NIOX® will be assessed by comparing
Title
individual pair-wise FENO measurements from visit V1.
Title
The change in FENO measured with NIOX MINO following corticosteroid therapy
Title
in asthma will be compared with improvements in standard asthma outcome
Title
measures (asthma symptoms and spirometry).
Title
To investigate the inter-operator variability FENO measurements with
Title
NIOX MINO in the same subject when different operators take FENO measurements. Three operator each takes two completed measurements in the same subject in a point of care setting.

10. Eligibility

Sex
All
Minimum Age & Unit of Time
4 Years
Maximum Age & Unit of Time
65 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Children, and adults. A history of physician-diagnosed asthma or asthma diagnosed by a physician. Spirometry performed parameters. An increased FENO value. Symptomatic asthma as defined on the Asthma Control Questionnaire® (ACQ). Exclusion Criteria: Use of oral corticosteroids. Use of intranasal corticosteroids. Use of non-steroidal anti-asthma drugs. Current serious conditions and/or therapies that are confounding factors. Pregnancy. Other significant respiratory diseases and/or cardiovascular diseases. Current participation in another interventional clinical study. Inability to comply with the study procedures, e.g. spirometry and FENO measurements according to standard procedures. Unwillingness to sign informed consent and comply with treatment and visits. Smoking within 6 months before the study, or a smoking history of >10 pack years or an equivalent amount of other tobacco use. Known alcohol or drug abuser. Food and beverage (other than water) intake within 1 hour before first FENO measurement Nicotine (including nicotine chewing gum, nicotine patch, snuff etc) use within 1 hour before first FENO measurement. Strenuous exercise within 1 hour before first FENO measurement
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
David Price, Professor
Organizational Affiliation
Dept of General Practice and Primary Care, University of Aberdeen
Official's Role
Study Chair
First Name & Middle Initial & Last Name & Degree
Sven-Erik Dahlén, Professor
Organizational Affiliation
Unit for Experimental Asthma and Allergy Research Division of Physiology, The National Institute of Environmental Medicine Karolinska Institutet
Official's Role
Study Chair
Facility Information:
Facility Name
Näsets Läkargrupp, Falsterbov. 79, SE-23651 Höllviken
City
Höllviken
ZIP/Postal Code
SE-23651
Country
Sweden
Facility Name
Department of General Practice & Primary Care University of Aberdeen
City
Aberdeen
ZIP/Postal Code
AB252AY
Country
United Kingdom

12. IPD Sharing Statement

Learn more about this trial

Study of Monitoring Exhaled NO in Symptomatic Asthmatic Adults and Children During Anti-inflammatory Treatment

We'll reach out to this number within 24 hrs